New and chronic use of hypnotics after diagnosis with early breast cancer.: A retrospective cohort study

Lærke Toftegård Andersen; Nis Frederik Palm Suppli; Susanne Oksbjerg Dalton; Niels Kroman; Jacob Rosenberg; Ismayil Gögenür

doi:10.3109/0284186x.2014.998276

New and chronic use of hypnotics after diagnosis with early breast cancer. A retrospective cohort study

Lærke Toftegård Andersen, Nis Frederik Palm Suppli, Susanne Oksbjerg Dalton, Niels Kroman, Jacob Rosenberg, Ismayil Gögenür

Department of Clinical Medicine

5 Citations (Scopus)

Abstract

BACKGROUND: To determine use and investigate factors associated with use of hypnotics the first year after a diagnosis with breast cancer.

MATERIAL AND METHODS: A retrospective registry based cohort study linking clinical data from the Danish Breast Cancer Group with the National Prescription Drug Database and other health and administrative registries. We included 26 082 women diagnosed with early breast cancer as first time primary cancer during 1996-2006. Use of hypnotics was measured as redeemed prescriptions in the first year after diagnosis of early breast cancer. Prior use of hypnotics was defined as one or more prescriptions of hypnotics 13 months to 1 month before diagnosis, and chronic use was defined as four or more prescriptions. Hazard ratios (HRs) for clinical variables, treatment-related factors and sociodemographic factors were calculated.

RESULTS: Among women with no prior history of hypnotic use, 17% became new users with 4% on a chronic level. Among prior users, 82% continued their use with one or more prescriptions of hypnotics and 15% increased their use to a chronic level. Significantly increased hazard ratios for use of hypnotics were seen with increasing age [age 50-59 years: HR 1.43 (95% CI 1.31-1.57), age 60-69: HR 1.57 (95% CI 1.44-1.71)], increasing number of tumor positive lymph nodes [1-3 lymph nodes: HR 1.12 (95% CI 1.05-1.09), 4-9 lymph nodes: HR 1.11 (95% CI 1.02-1.29)], chemotherapy [HR 1.25 (95% CI 1.12-1.39)], somatic comorbidity [HR 1.31 (95% CI 1.21-1.42)] and use of antidepressants the year before breast cancer diagnosis [HR 1.97 (95% CI 1.85-2.10)].

CONCLUSION: This study detected a group of patients at great risk for initiating and increasing use of hypnotics and preventive and prophylactic mechanism should be investigated and initiated when this group of patients is seen in the clinical setting.

Original language	English
Journal	Acta Oncologica
Volume	54
Issue number	5
Pages (from-to)	704-11
Number of pages	8
ISSN	0284-186X
DOIs	https://doi.org/10.3109/0284186x.2014.998276
Publication status	Published - 1 May 2015

Keywords

Adult
Age Factors
Aged
Antidepressive Agents
Breast Neoplasms
Denmark
Drug Prescriptions
Female
Humans
Hypnotics and Sedatives
Lymph Nodes
Middle Aged
Proportional Hazards Models
Registries
Retrospective Studies
Time Factors
Tumor Burden

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/0284186x.2014.998276

0284186X.2014.998276?needAccess=trueFinal published version, 448 KB

https://www.tandfonline.com/doi/pdf/10.3109/0284186X.2014.998276?needAccess=true

Cite this

@article{0efd741876aa4e79bdf18bfb6c72ae73,

title = "New and chronic use of hypnotics after diagnosis with early breast cancer.: A retrospective cohort study",

abstract = "BACKGROUND: To determine use and investigate factors associated with use of hypnotics the first year after a diagnosis with breast cancer.MATERIAL AND METHODS: A retrospective registry based cohort study linking clinical data from the Danish Breast Cancer Group with the National Prescription Drug Database and other health and administrative registries. We included 26 082 women diagnosed with early breast cancer as first time primary cancer during 1996-2006. Use of hypnotics was measured as redeemed prescriptions in the first year after diagnosis of early breast cancer. Prior use of hypnotics was defined as one or more prescriptions of hypnotics 13 months to 1 month before diagnosis, and chronic use was defined as four or more prescriptions. Hazard ratios (HRs) for clinical variables, treatment-related factors and sociodemographic factors were calculated.RESULTS: Among women with no prior history of hypnotic use, 17% became new users with 4% on a chronic level. Among prior users, 82% continued their use with one or more prescriptions of hypnotics and 15% increased their use to a chronic level. Significantly increased hazard ratios for use of hypnotics were seen with increasing age [age 50-59 years: HR 1.43 (95% CI 1.31-1.57), age 60-69: HR 1.57 (95% CI 1.44-1.71)], increasing number of tumor positive lymph nodes [1-3 lymph nodes: HR 1.12 (95% CI 1.05-1.09), 4-9 lymph nodes: HR 1.11 (95% CI 1.02-1.29)], chemotherapy [HR 1.25 (95% CI 1.12-1.39)], somatic comorbidity [HR 1.31 (95% CI 1.21-1.42)] and use of antidepressants the year before breast cancer diagnosis [HR 1.97 (95% CI 1.85-2.10)].CONCLUSION: This study detected a group of patients at great risk for initiating and increasing use of hypnotics and preventive and prophylactic mechanism should be investigated and initiated when this group of patients is seen in the clinical setting.",

keywords = "Adult, Age Factors, Aged, Antidepressive Agents, Breast Neoplasms, Denmark, Drug Prescriptions, Female, Humans, Hypnotics and Sedatives, Lymph Nodes, Middle Aged, Proportional Hazards Models, Registries, Retrospective Studies, Time Factors, Tumor Burden",

author = "Andersen, {L{\ae}rke Tofteg{\aa}rd} and Suppli, {Nis Frederik Palm} and Dalton, {Susanne Oksbjerg} and Niels Kroman and Jacob Rosenberg and Ismayil G{\"o}gen{\"u}r",

year = "2015",

month = may,

day = "1",

doi = "10.3109/0284186x.2014.998276",

language = "English",

volume = "54",

pages = "704--11",

journal = "Acta Oncologica",

issn = "0284-186X",

publisher = "Taylor & Francis",

number = "5",

}

TY - JOUR

T1 - New and chronic use of hypnotics after diagnosis with early breast cancer.

T2 - A retrospective cohort study

AU - Andersen, Lærke Toftegård

AU - Suppli, Nis Frederik Palm

AU - Dalton, Susanne Oksbjerg

AU - Kroman, Niels

AU - Rosenberg, Jacob

AU - Gögenür, Ismayil

PY - 2015/5/1

Y1 - 2015/5/1

N2 - BACKGROUND: To determine use and investigate factors associated with use of hypnotics the first year after a diagnosis with breast cancer.MATERIAL AND METHODS: A retrospective registry based cohort study linking clinical data from the Danish Breast Cancer Group with the National Prescription Drug Database and other health and administrative registries. We included 26 082 women diagnosed with early breast cancer as first time primary cancer during 1996-2006. Use of hypnotics was measured as redeemed prescriptions in the first year after diagnosis of early breast cancer. Prior use of hypnotics was defined as one or more prescriptions of hypnotics 13 months to 1 month before diagnosis, and chronic use was defined as four or more prescriptions. Hazard ratios (HRs) for clinical variables, treatment-related factors and sociodemographic factors were calculated.RESULTS: Among women with no prior history of hypnotic use, 17% became new users with 4% on a chronic level. Among prior users, 82% continued their use with one or more prescriptions of hypnotics and 15% increased their use to a chronic level. Significantly increased hazard ratios for use of hypnotics were seen with increasing age [age 50-59 years: HR 1.43 (95% CI 1.31-1.57), age 60-69: HR 1.57 (95% CI 1.44-1.71)], increasing number of tumor positive lymph nodes [1-3 lymph nodes: HR 1.12 (95% CI 1.05-1.09), 4-9 lymph nodes: HR 1.11 (95% CI 1.02-1.29)], chemotherapy [HR 1.25 (95% CI 1.12-1.39)], somatic comorbidity [HR 1.31 (95% CI 1.21-1.42)] and use of antidepressants the year before breast cancer diagnosis [HR 1.97 (95% CI 1.85-2.10)].CONCLUSION: This study detected a group of patients at great risk for initiating and increasing use of hypnotics and preventive and prophylactic mechanism should be investigated and initiated when this group of patients is seen in the clinical setting.

AB - BACKGROUND: To determine use and investigate factors associated with use of hypnotics the first year after a diagnosis with breast cancer.MATERIAL AND METHODS: A retrospective registry based cohort study linking clinical data from the Danish Breast Cancer Group with the National Prescription Drug Database and other health and administrative registries. We included 26 082 women diagnosed with early breast cancer as first time primary cancer during 1996-2006. Use of hypnotics was measured as redeemed prescriptions in the first year after diagnosis of early breast cancer. Prior use of hypnotics was defined as one or more prescriptions of hypnotics 13 months to 1 month before diagnosis, and chronic use was defined as four or more prescriptions. Hazard ratios (HRs) for clinical variables, treatment-related factors and sociodemographic factors were calculated.RESULTS: Among women with no prior history of hypnotic use, 17% became new users with 4% on a chronic level. Among prior users, 82% continued their use with one or more prescriptions of hypnotics and 15% increased their use to a chronic level. Significantly increased hazard ratios for use of hypnotics were seen with increasing age [age 50-59 years: HR 1.43 (95% CI 1.31-1.57), age 60-69: HR 1.57 (95% CI 1.44-1.71)], increasing number of tumor positive lymph nodes [1-3 lymph nodes: HR 1.12 (95% CI 1.05-1.09), 4-9 lymph nodes: HR 1.11 (95% CI 1.02-1.29)], chemotherapy [HR 1.25 (95% CI 1.12-1.39)], somatic comorbidity [HR 1.31 (95% CI 1.21-1.42)] and use of antidepressants the year before breast cancer diagnosis [HR 1.97 (95% CI 1.85-2.10)].CONCLUSION: This study detected a group of patients at great risk for initiating and increasing use of hypnotics and preventive and prophylactic mechanism should be investigated and initiated when this group of patients is seen in the clinical setting.

KW - Adult

KW - Age Factors

KW - Aged

KW - Antidepressive Agents

KW - Breast Neoplasms

KW - Denmark

KW - Drug Prescriptions

KW - Female

KW - Humans

KW - Hypnotics and Sedatives

KW - Lymph Nodes

KW - Middle Aged

KW - Proportional Hazards Models

KW - Registries

KW - Retrospective Studies

KW - Time Factors

KW - Tumor Burden

U2 - 10.3109/0284186x.2014.998276

DO - 10.3109/0284186x.2014.998276

M3 - Journal article

C2 - 25752966

SN - 0284-186X

VL - 54

SP - 704

EP - 711

JO - Acta Oncologica

JF - Acta Oncologica

IS - 5

ER -